ACE and Hyperkalemia: Similarly, in 2008, the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) [40,41] showed no differences between an ACE inhibitor and an ARB, alone or in combination, for major cardiovascular and renal events, but highlighted the danger of dual blockade of RAS, reporting an increased risk of acute dialysis and hyperkalemia in patients with vascular disease or high-risk diabetes and who were prescribed an ACE inhibitor and an ARB together.